Ocular hypertension and primary open-angle glaucoma
Chronic open-angle glaucoma is the commonest glaucoma in the UK and is managed to a single national guideline, NICE NG81. This lesson covers who is at risk, how people are found and referred, the difference between ocular hypertension, suspected glaucoma and glaucoma, and when and how each is treated and monitored. Normal tension glaucoma is covered at the end.
The disease and who gets it
In primary open-angle glaucoma (POAG) the drainage angle looks normal on gonioscopy, but aqueous meets increased resistance as it passes through the trabecular meshwork. Pressure rises slowly, without pain or redness, and the optic nerve is damaged over years. NICE calls the same condition chronic open-angle glaucoma (COAG), and the two terms are interchangeable in UK exams.
3D atlasIn open-angle glaucoma the angle is open but the meshwork drains poorly.Because it is symptomless until field loss is advanced, most cases are picked up at a routine sight test. The patient who does present with symptoms has usually lost a great deal of field already.
- Raised intraocular pressure: the main risk factor and the only treatable one.
- Age: prevalence rises steadily with age.
- Family history: first-degree relatives are at increased risk, siblings most of all. This is why NICE asks clinicians to tell patients that relatives may wish to be tested.
- Ethnicity: POAG is about two to three times more common in black people than in white people.
- Myopia.
- Corticosteroid use, by any route.
- Type 2 diabetes, hypertension and cardiovascular disease are associated, though the added risk may be small.
- A thin central cornea, which also causes the pressure to be under-read.
Most POAG is polygenic. The commonest single-gene cause is a mutation in myocilin (MYOC), found in only a few per cent of adult cases but in a much larger share of those with early onset, high pressures and a strong family history.
Three labels on one spectrum
NG81 groups three conditions together as "COAG and related conditions". They differ in whether the pressure is raised and whether there is damage.
| Pressure | Optic disc | Visual field | |
|---|---|---|---|
| Ocular hypertension (OHT) | Consistently raised | Normal | Normal |
| Suspected COAG | Raised or normal | Suspicious but not conclusive | Normal or equivocal |
| COAG | Raised or normal | Glaucomatous damage | Matching defect |
Ocular hypertension means pressure repeatedly above the normal range with an open angle and no sign of damage. It matters because it is the pool from which glaucoma arises: roughly one in ten untreated people with raised pressure develop glaucoma within five years. Most do not, which is why not all are treated.
Case-finding and referral
The UK National Screening Committee does not recommend population screening for glaucoma, partly because the available tests are not accurate enough. Cases are found opportunistically by community optometrists. Before referring, NG81 asks the primary eye care professional to offer four things.
- Central visual field assessment by standard automated perimetry.
- Optic nerve and fundus examination by stereoscopic slit lamp biomicroscopy, with OCT or a disc image if available.
- Pressure measurement by Goldmann-type applanation tonometry.
- Assessment of the peripheral anterior chamber by gonioscopy or, if that is not available, the van Herick test or OCT.
A decision to refer must not be based on non-contact tonometry alone. Because fields and pressures fluctuate, the optometrist should consider repeating them on another occasion before referring, unless the picture is urgent. Schemes that do this, known as repeat measures and referral refinement, exist to cut the number of false positive referrals.
Referral is then indicated if any one of these is present: optic nerve head damage on slit lamp examination, a visual field defect consistent with glaucoma, or a pressure of 24 mmHg or more on Goldmann-type tonometry. People with a pressure below 24 mmHg and no other finding continue with regular sight tests.
Making the diagnosis
In the hospital eye service or a specialist community service the same domains are examined more rigorously. NG81 lists five tests to offer at diagnosis.
- Visual field by standard automated perimetry with a central thresholding test, repeated if needed to establish severity.
- Dilated stereoscopic slit lamp examination of the optic nerve and fundus.
- Slit lamp mounted Goldmann applanation tonometry.
- Gonioscopy, to confirm that the angle is open.
- Central corneal thickness.
A baseline image of the optic nerve head, such as a stereo photograph or OCT, is recorded so that later change can be detected. Gonioscopy matters because an open-angle label is a diagnosis of exclusion: narrow angles and secondary causes such as pigment dispersion or pseudoexfoliation change the management.
For someone with ocular hypertension the clinician then estimates the risk of visual impairment within that person's lifetime. NICE names four factors: the level of pressure, central corneal thickness, family history and life expectancy. An 85 year old with a pressure of 25 mmHg and thick corneas is unlikely ever to lose sight from it. A 50 year old with 30 mmHg, thin corneas and a parent blind from glaucoma is in a different position.
When and how to treat
All treatment works by lowering pressure, which slows ganglion cell loss whatever the starting pressure. Clinicians usually set a target pressure for each patient, low enough that the disc and field are expected to stay stable, and lower still if damage is advanced or progresses.
Since the 2022 update, the first-line treatment NICE recommends is a laser, not a drop. 360 degree selective laser trabeculoplasty (SLT) treats the whole circumference of the meshwork in a single outpatient session and improves outflow. NICE found it more effective and less costly than starting with drops, largely because it delays or avoids years of daily medication. Patients should be told that the effect can wear off, that a second treatment may be needed, and that it reduces but does not remove the chance of needing drops. SLT is not recommended as first line in pigment dispersion syndrome, where NICE found no evidence for it.
The first-line drug is a generic prostaglandin analogue such as latanoprost, one drop at night. It is offered when the patient declines SLT, when SLT is unsuitable, while waiting for SLT, or when SLT has not lowered the pressure enough.
| Situation | What NICE recommends |
|---|---|
| OHT, not at risk of visual impairment in their lifetime | No treatment. Regular visits to the optometrist |
| OHT with IOP of 24 mmHg or more and at risk of visual impairment | Offer 360 degree SLT. Generic prostaglandin analogue if SLT is declined, unsuitable, awaited or insufficient |
| Suspected COAG with IOP below 24 mmHg | No treatment unless at risk of visual impairment in their lifetime |
| Newly diagnosed COAG, not advanced | Offer 360 degree SLT. Generic prostaglandin analogue in the same circumstances as above |
| Advanced COAG | Offer glaucoma surgery augmented with mitomycin C, with a generic prostaglandin analogue in the interim |
If the pressure is still too high on a prostaglandin analogue, the first step is to check adherence and drop technique. If those are satisfactory, NICE offers a choice: add or switch to a drug from another class (a beta-blocker, carbonic anhydrase inhibitor or sympathomimetic), SLT, or surgery. If a prostaglandin is not tolerated in ocular hypertension, the sequence is another generic prostaglandin analogue, then a beta-blocker, then the other classes. Preservative-free drops are for people with preservative allergy or significant ocular surface disease. The drugs themselves and the operations are covered in the next two lessons.
Monitoring
Glaucoma care is lifelong. At each visit NICE asks for Goldmann tonometry and an anterior segment examination, with repeat fields, disc assessment and gonioscopy when clinically indicated. Field tests must use the same strategy each time so that results can be compared. The interval to the next visit depends on two questions: is the pressure at target, and is there progression or conversion.
| Group | Pressure not controlled | Controlled and stable |
|---|---|---|
| Treated OHT | 1 to 4 months | 18 to 24 months |
| Suspected COAG | 1 to 4 months | 12 to 18 months |
| COAG | 1 to 4 months, or 1 to 2 months if progressing | 12 to 18 months if low risk, 6 to 12 months if high risk |
People referred with ocular hypertension who do not need treatment, and those in whom glaucoma is no longer suspected, are discharged to their optometrist with a written summary. Patients should also be told that sight already lost cannot be recovered, that most people on treatment keep useful sight for life, and that DVLA rules on visual fields may apply to them.
Normal tension glaucoma
Normal tension glaucoma (NTG) is open-angle glaucoma in which the measured pressure is never above the normal range. The disc and field changes are the same in kind, with some differences of emphasis: disc haemorrhages are more common, and field defects tend to be deep, localised and close to fixation.
The explanation is thought to be an optic nerve head that is unusually vulnerable, in part through poor blood supply. This fits the recognised associations: migraine, Raynaud phenomenon, low blood pressure at night and obstructive sleep apnoea. NTG makes up a far larger share of open-angle glaucoma in East Asian populations than in white European ones.
Two practical points follow. First, check that the pressure really is normal: a thin cornea hides a higher true pressure, and pressure varies through the day. Second, exclude other causes of an optic neuropathy. Pallor without cupping, a field defect that respects the vertical midline, or neurological symptoms call for imaging of the anterior visual pathway to look for a compressive lesion.
Treatment is still pressure lowering. The Collaborative Normal Tension Glaucoma Study showed that reducing pressure by 30 per cent slowed field loss, although some treated patients continued to progress.
Summary
- Primary open-angle glaucoma is symptomless until late and is usually detected at a sight test.
- Risk factors are raised pressure, age, family history, black ethnicity, myopia, corticosteroids and a thin cornea.
- Ocular hypertension is raised pressure with normal discs and fields, and about one in ten untreated cases convert to glaucoma within five years.
- NICE advises referral for optic nerve head damage, a glaucomatous field defect, or a Goldmann pressure of 24 mmHg or more.
- Referral should never rest on non-contact tonometry alone.
- Diagnosis needs perimetry, dilated disc examination, Goldmann tonometry, gonioscopy and central corneal thickness.
- Ocular hypertension is treated only when pressure is 24 mmHg or more and there is a risk of visual impairment in the person's lifetime.
- First-line treatment for ocular hypertension that needs treating and for newly diagnosed glaucoma is 360 degree selective laser trabeculoplasty.
- The first-line drug is a generic prostaglandin analogue, and advanced glaucoma is offered surgery with mitomycin C.
- Normal tension glaucoma is treated by lowering pressure, after excluding other optic neuropathies.
Check yourself
Quick recall on this lesson. These are easier than the question bank.
Written for revision. It is not a source of clinical advice, and guidance changes.